# Integra Lifesciences Holdings Corp: overview

IART · Nasdaq · CIK 917520 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/iart.md) · [Financials](/companies/iart/financials.md) · [Filings](/companies/iart/filings.md) · [Insiders](/companies/iart/insiders.md)

Latest reported revenue: [$411.2m](/filings/0000917520-26-000077.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 23, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000917520-26-000077).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [443 d](/filings/0000917520-26-000011.md) | [383](/filings/0000917520-26-000041.md) | [416](/filings/0000917520-26-000058.md) | [402](/filings/0000917520-26-000077.md) | [435 d](/filings/0000917520-26-000011.md) | [392](/filings/0000917520-26-000041.md) | [419](/filings/0000917520-26-000058.md) | [411](/filings/0000917520-26-000077.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [8.0% d](/filings/0000917520-26-000011.md) | [(4.0%)](/filings/0000917520-26-000041.md) | [(123.4%)](/filings/0000917520-26-000058.md) | [2.9%](/filings/0000917520-26-000077.md) | [5.3% d](/filings/0000917520-26-000011.md) | [2.9%](/filings/0000917520-26-000041.md) | [4.6%](/filings/0000917520-26-000058.md) | [4.6%](/filings/0000917520-26-000077.md) |
| Net margin | % | [4.4% d](/filings/0000917520-26-000011.md) | [(6.6%)](/filings/0000917520-26-000077.md) | [(116.5%)](/filings/0000917520-26-000077.md) | [(1.3%)](/filings/0000917520-26-000077.md) | [(0.4%) d](/filings/0000917520-26-000011.md) | [(1.2%)](/filings/0000917520-26-000077.md) | [1.1%](/filings/0000917520-26-000077.md) | [3.6%](/filings/0000917520-26-000077.md) |
| Diluted EPS | $ per share | not reported | [(0.33)](/filings/0000917520-26-000041.md) | [(6.31)](/filings/0000917520-26-000058.md) | [(0.07)](/filings/0000917520-26-000077.md) | not reported | [(0.06)](/filings/0000917520-26-000041.md) | [0.06](/filings/0000917520-26-000058.md) | [0.19](/filings/0000917520-26-000077.md) |
| Free cash flow | $m | [21.1 d](/filings/0000917520-26-000011.md) | [(40.2)](/filings/0000917520-26-000041.md) | [(11.2) d](/filings/0000917520-26-000058.md) | [25.8 d](/filings/0000917520-26-000077.md) | [(5.4) d](/filings/0000917520-26-000011.md) | [(5.0)](/filings/0000917520-26-000041.md) | [10.5 d](/filings/0000917520-26-000058.md) | [85.7 d](/filings/0000917520-26-000077.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,542](/filings/0000917520-24-000022.md) | [1,558](/filings/0000917520-25-000017.md) | [1,542](/filings/0000917520-26-000011.md) | [1,611](/filings/0000917520-26-000011.md) | [1,635](/filings/0000917520-26-000011.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [12.8%](/filings/0000917520-24-000022.md) | [15.3%](/filings/0000917520-25-000017.md) | [7.2%](/filings/0000917520-26-000011.md) | [1.8%](/filings/0000917520-26-000011.md) | [(30.2%)](/filings/0000917520-26-000011.md) |
| Net margin | % | [11.0%](/filings/0000917520-24-000022.md) | [11.6%](/filings/0000917520-25-000017.md) | [4.4%](/filings/0000917520-26-000011.md) | [(0.4%)](/filings/0000917520-26-000011.md) | [(31.6%)](/filings/0000917520-26-000011.md) |
| Diluted EPS | $ per share | [1.98](/filings/0000917520-24-000022.md) | [2.16](/filings/0000917520-25-000017.md) | [0.84](/filings/0000917520-26-000011.md) | [(0.09)](/filings/0000917520-26-000011.md) | [(6.74)](/filings/0000917520-26-000011.md) |
| Free cash flow | $m | [264](/filings/0000917520-24-000022.md) | [222](/filings/0000917520-25-000017.md) | [73.1](/filings/0000917520-26-000011.md) | [25.0](/filings/0000917520-26-000011.md) | [(31.1)](/filings/0000917520-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/iart/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $191.9m | 10,684,103 |  | Added +364,934 |
| [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $139.3m | 7,753,934 |  | Unchanged |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $67.3m | 3,749,367 |  | Added +263,764 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $67.2m | 3,743,093 |  | Added +56,456 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $64.5m | 3,593,079 |  | Added +8,924 |
| [PARADIGM CAPITAL MANAGEMENT INC/NY](/funds/1037792.md) | 2026-06-30 | $61.8m | 3,439,098 |  | Reduced −573,600 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $61.7m | 3,436,006 |  | Reduced −93,398 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $52.9m | 2,946,862 |  | Added +60,306 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $52.9m | 2,946,173 |  | Added +55,349 |
| [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $42.6m | 2,364,777 |  | Added +249,522 |

## Recent filings

[All 1,445 filings](/companies/iart/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-23 | 16:01 ET | [10-Q](/filings/0000917520-26-000077.md) | Quarterly report, period 2026-09-30 | 0000917520-26-000077 |
| 2026-10-21 | 10:15 ET | [8-K](/filings/0000917520-26-000073.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000917520-26-000073 |
| 2026-10-19 | 20:20 ET | [8-K](/filings/0001193125-26-425271.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-425271 |
| 2026-10-09 | 21:26 ET | [8-K](/filings/0001193125-26-419228.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-419228 |
| 2026-10-02 | 12:20 ET | [8-K](/filings/0000917520-26-000067.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000917520-26-000067 |
| 2026-09-08 | 10:30 ET | [8-K](/filings/0000917520-26-000061.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000917520-26-000061 |
| 2026-07-29 | 20:03 ET | [10-Q](/filings/0000917520-26-000058.md) | Quarterly report, period 2026-06-30 | 0000917520-26-000058 |
| 2026-07-29 | 10:15 ET | [8-K](/filings/0000917520-26-000055.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000917520-26-000055 |
| 2026-05-08 | 20:15 ET | [8-K](/filings/0000917520-26-000044.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0000917520-26-000044 |
| 2026-05-05 | 20:03 ET | [10-Q](/filings/0000917520-26-000041.md) | Quarterly report, period 2026-03-31 | 0000917520-26-000041 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0000917520-26-000011.md), filed Feb 26, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 917520
- Tickers: IART
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.